Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.48 |
| ▸ | FOLH1 | Q04609 | 7/20 | 0.38 |
| ▸ | GRPR | P30550 | 3/20 | 0.38 |
| ▸ | ALB | P02768 | 1/20 | 0.35 |
| ▸ | CCKAR | P32238 | 1/20 | 0.34 |
| ▸ | CCKBR | P32239 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12743509 | 0.97 | GLP1R (0.51) | GLP1RFOLH1GRPRALB | |
| SCHEMBL14367158 | 0.94 | GLP1R (0.52) | GLP1RFOLH1GRPRCCKARCCKBR | |
| SCHEMBL12743484 | 0.94 | GLP1R (0.53) | GLP1RFOLH1GRPRALB | |
| SCHEMBL14367156 | 0.91 | GLP1R (0.55) | GLP1RFOLH1GRPRALBCCKAR | |
| SCHEMBL8116094 | 0.90 | GLP1R (0.51) | GLP1RFOLH1GRPRALBCCKAR | |
| SCHEMBL12767756 | 0.88 | GLP1R (0.43) | GLP1RFOLH1GRPRCCKARCCKBR | |
| SCHEMBL14500447 | 0.88 | GLP1R (0.49) | GLP1RFOLH1GRPRALBCCKAR | |
| SCHEMBL14422366 | 0.87 | GLP1R (0.52) | GLP1RFOLH1GRPRCCKARCCKBR | |
| SCHEMBL13475019 | 0.86 | GLP1R (0.53) | GLP1RFOLH1GRPRALBCCKAR | |
| SCHEMBL8122830 | 0.86 | GLP1R (0.53) | GLP1RFOLH1GRPRALBCCKAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7910088-B2 | Multivalent constructs for therapeutic and diagnostic applications | BRACCO SUISSE SA (CH) | 2011-03-22 | — | — | US | disclosed |
| US-7666979-B2 | polyvalent targeting ligands that bind to cells used for diagnosis of diseases sensitivity to angiogenesis factor | BRACCO INTERNATIONAL B.V. (NL) | 2010-02-23 | — | — | US | disclosed |
| US-7261876-B2 | Multivalent constructs for therapeutic and diagnostic applications | BRACCO INTERNATIONAL BV (NL) | 2007-08-28 | — | — | US | disclosed |
| US-20070172428-A1 | MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | BRACCO INTERNATIONAL B.V. (NL) | 2007-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070172428-A1 | MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | CD47, BCR, CD44 | GLP1R 2595/4885FOLH1 84/4885GRPR 2491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.